Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardima gets Canadian nod for AF (atrial fibrillation) mictrocatheters:

This article was originally published in Clinica

Executive Summary

Cardima has gained the green light in Canada to market its REVELATION family of ablation microcatheters as a treatment for atrial fibrillation (AF). The Revelation Tx, Revelation T-Flex and Revelation Helix microcatheters can be used in a minimally invasive version of a surgical treatment for AF, called MAZE. They allow surgeons to create straight, curved and circumferential linear endocardial lesions to treat the condition. Cardima, of Fremont, California has already submitted a marketing application to the US FDA for the Revelation Tx device.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel